Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree

View original at finance.yahoo.com
5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree If any investor has stood the test of time, it’s Warren Buffett, and with good reason…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The portfolio will remain concentrated in a small group of companies

    60% confidence

  • The course forward would remain the same, and he would directly oversee the equity portfolio, with Ted Weschler continuing to manage about 6% of it. The portfolio will remain concentrated in a small group of companies.

    60% confidence

  • Greg Abel will use all of his $25 million per year salary to buy shares in Berkshire Hathaway

    60% confidence

  • His favorite holding for an S&P 500 stock is forever

    60% confidence

  • Warren Buffett will remain board chair and come to the office every day, continuing to have a voice in day-to-day operations

    60% confidence

  • Warren Buffett vows to come to the office every day and continue to have a voice in day-to-day operations

    60% confidence

  • Greg Abel will use all of his $25 million per year salary to buy shares in Berkshire Hathaway

    60% confidence

  • The course forward would remain the same, and he would directly oversee the equity portfolio, with Ted Weschler continuing to manage about 6% of it

    60% confidence

  • Warren Buffett's favorite holding period for an S&P 500 stock is forever

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree — Source | Via News | Via News